BioSpace News Archive

Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the underlying causes of the world’s most prevalent eye diseases, announced the pricing of its initial public offering of 10,000,000 shares of common stock at a public offering price of $24.00 per share.

Small molecules API are usually composed of 20-100 atoms that are well characterized and easily purified & analyzed.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), announced today that after review and discussion of TransMedics’ clinical evidence from the OCS Liver PROTECT trial, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee convened by the U.S. Food and Drug Administration

The Medical Device Testing Services market was valued at US$ 5505.4 million in 2018 and it is projected to reach US$ 14,660.1 million by 2027; it is expected to grow at a CAGR of 11.7% from 2019 to 2027.

The global patient simulators market is expected to reach US$ 2,373.1 Mn in 2025 from US$ 694.6 in 2017. The market is estimated to grow with a CAGR of 16.8% from 2018-2025.

The global preterm birth control market is expected to reach US$ 1,809.0 Mn in 2025 from US$ 1,190.5 in 2017. The market is estimated to grow with a CAGR of 4.9% from 2018-2025.

Auris Medical Holding Ltd. today nnounced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.

BurstIQ announced today that longtime partner FlowMetric Life Sciences, launched their novel vaccine immune response test, VaxEffect™.

Synaptogenix, Inc. today announced that its abstract has been accepted at the Alzheimer’s Association International Conference (“AAIC”), which will be held online and in-person July 26-30, 2021 .

Shorla Pharma Limited, a specialty pharmaceutical company, has announced its arrival in the United States locating a base in Boston’s innovative Cambridge biotech cluster.